News | February 27, 2026
Novo Nordisk & Vivtex team up to revolutionize oral hiologics
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
The innovative eyedrop targets inflammation and pain following ocular surgery
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
The NDA filing is supported by results from the phase III evERA Breast Cancer study
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
Subscribe To Our Newsletter & Stay Updated
